High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany

Conditions:   Type 1 Diabetes;   Familial Hypercholesterolemia
Intervention:  
Sponsor:   Kinderkrankenhaus auf der Bult
Not yet recruiting - verified April 2016

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Conditions:   Hypercholesterolemia;   Familial Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Rosuvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified April 2016

A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

Condition:   Hypercholesterolemia
Interventions:   Drug: Rosuvastatin;   Drug: Ezetimibe
Sponsor:   IlDong Pharmaceutical Co Ltd
Recruiting - verified March 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Not yet recruiting - verified April 2016

Point-of-Care Adipose-derived Cells for Hair Growth

Condition:   Androgenetic Alopecia
Interventions:   Procedure: Stromal Vascular Fraction Cells (SVF Cells) Injection;   Procedure: Liposuction;   Other: Hair Measurements
Sponsor:   University of Florida
Not yet recruiting - verified April 2016

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Conditions:   Hypercholesterolemia;   Healthy
Interventions:   Biological: Cohort 1: bococizumab 150 mg + rHuPH20;   Biological: Cohort 2: bococizumab 300 mg;   Biological: Cohort 3: bococizumab 300 mg + rHuPH20;   Biological: Cohort 4: bococizumab 300 mg + rHuPH20;   Biological: Cohort 5: bococizumab 450 mg + rHuPH20
Sponsors:   Pfizer;   Halozyme Therapeutics
Recruiting - verified April 2016

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Condition:   Hypercholesterolemia
Interventions:   Biological: Evolocumab;   Drug: Ezetimibe;   Biological: Evolocumab;   Drug: Ezetimibe
Sponsors:   Amgen;   Data Monitoring Committee (DMC)
Recruiting - verified April 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2016

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2016

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

Condition:   Hypercholesterolemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo (for injection training only)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2016

Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Evolocumab;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified April 2016

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Conditions:   Vascular Diseases;   Hypercholesterolemia;   Diabetes Mellitus
Interventions:   Dietary Supplement: Plant sterols;   Dietary Supplement: Placebo product
Sponsors:   Unilever R&D;   CSIRO
Recruiting - verified April 2016

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Condition:   Hypercholesterolemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Enrolling by invitation - verified April 2016

A Registration Study for Dyslipidemia

Condition:   Atherosclerotic Vascular Diseases
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting - verified April 2016

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis (MIRACULOUS) Trial

Condition:   Atherosclerosis
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   University of Maryland
Recruiting - verified April 2016

Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study

Condition:   Tobacco Dependence
Interventions:   Behavioral: Tobacco/Physical Activity Intervention;   Behavioral: Diet plus BP/CHOL Intervention
Sponsors:   Stanford University;   University of California, San Francisco;   Alaska Native Tribal Health Consortium;   University of Alaska Anchorage;   Norton Sound Health Corporation
Recruiting - verified April 2016

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Completed - verified April 2016

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2016

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Condition:   Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions:   Drug: Anacetrapib;   Drug: Placebo for anacetrapib
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2016

The Therapeutic Effects of Statins and Berberine on the Hyperlipemia

Condition:   Dyslipidemias
Interventions:   Drug: Berberine;Atorvastatin or Rosuvastatin;   Drug: Atorvastatin or Rosuvastatin
Sponsor:   Wenzhou Medical University
Terminated - verified April 2016

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Conditions:   Dyslipidemia;   Healthy Volunteers
Intervention:   Drug: TAP311
Sponsor:   Novartis Pharmaceuticals
Completed - verified April 2016

Lipoic Acid and Prevention of Heart Disease

Condition:   Atherosclerosis
Interventions:   Dietary Supplement: R-alpha lipoic acid;   Dietary Supplement: Placebo
Sponsors:   Oregon State University;   Oregon Health and Science University;   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting - verified April 2016

hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)

Condition:   Ischemic Stroke
Intervention:   Drug: Statin
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Ministry of Health, Labour and Welfare, Japan;   Hiroshima University;   Osaka University
Completed - verified April 2016

Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)

Condition:   Ischemic Stroke
Intervention:   Drug: Statin
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Ministry of Health, Labour and Welfare, Japan;   Hiroshima University;   National Cerebral and Cardiovascular Center
Completed - verified April 2016

Japan Statin Treatment Against Recurrent Stroke (J-STARS)

Condition:   Ischemic Stroke
Intervention:   Drug: Pravastatin
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Ministry of Health, Labour and Welfare, Japan;   Hiroshima University
Completed - verified March 2015

Dietary Intervention Study in Children (DISC)

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Hypercholesterolemia
Intervention:   Behavioral: diet, fat-restricted
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005